# Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

> **NCT05999240** · PHASE2 · RECRUITING · sponsor: **New York State Psychiatric Institute** · enrollment: 30 (estimated)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05999240
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05999240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05999240, "Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05999240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*